在晚期帕金森病中进行Levodopa-Entacapone-Carbidopa内注注输液 - - ELEGANCE研究的临时分析
Daniel Weiss1, Wolfgang H Jost2, József Attila Szász3
1Department for Neurodegenerative Diseases, Centre for Neurology, Hertie-Institute for Clinical Brain Research, Tübingen, Germany.
Movement disorders clinical practice
|March 25, 2025
概括
在晚期帕金森病患者中,Levodopa-entacapone-carbidopa肠凝 (LECIG) 治疗显著减少了每日OFF时间,并改善了运动和非运动症状. 患者报告高满意度和改善生活质量,持续效益长达12个月.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 医疗器械 医疗器械
背景情况:
- 利沃多巴-卡-卡比多巴肠凝 (LECIG) 是一种在2018年推出的用于晚期帕金森病 (PD) 的设备辅助疗法.
- 关于LECIG的长期结果的现实数据对于理解其临床实用性至关重要.
研究的目的:
- 收集关于LECIG在晚期PD中的长期疗效,安全性和患者报告结果的真实数据.
- 报告来自ELEGANCE研究 (NCT05043103) 的中间分析数据.
主要方法:
- 该ELEGANCE研究招募了167名在13个欧洲国家的37个中心处方LECIG的患者.
- 患者在基线 (V1),3-6个月 (V2) 和6-12个月 (V3) 时被评估.
- 数据包括运动症状 (MDS-UPDRS),非运动症状 (PDSS-2) 和生活质量 (PDQ-8).
主要成果:
- LECIG显著减少了每日关机时间3.47小时 (P < 0.0001),并在V2时改善了MDS-UPDRS部分IV和II分数.
- 在帕金森病症状和副作用量表 (PDSS-2) 和PDQ-8生活质量评分 (P < 0.0001) 中观察到持续改善.
- 报告的患者满意度很高,大多数不良事件与设备或程序有关.
结论:
- 常规使用LECIG长达12个月,可在晚期PD中持续控制运动症状.
- LECIG疗法耐受性良好,对生活质量产生积极影响,并获得高患者满意度.
- 这些发现支持LECIG作为治疗高级帕金森病的有效治疗选择.
相关概念视频
Parkinson's Disease: Treatment
166
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
166
Parkinson's Disease: Overview
399
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
399
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
51
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
51
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
882
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
882
Drug Delivery: Parenteral Route
353
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
353
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.0K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.0K


